Direkt zum Inhalt
Merck
Alle Fotos(2)

Key Documents

View All Documentation

A5922

Sigma-Aldrich

Amifostin Trihydrat

≥97% (TLC), powder

Synonym(e):

2-(3-Aminopropyl)aminoethyl phosphorothioate, WR2721

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(2)

About This Item

Empirische Formel (Hill-System):
C5H15N2O3PS · 3 H2O
CAS-Nummer:
112901-68-5
Molekulargewicht:
268.27
MDL-Nummer:
MFCD00453866
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24278231
NACRES:
NA.77

Qualitätsniveau

200

Assay

≥97% (TLC)

Form

powder

Lagertemp.

2-8°C

SMILES String

OP(SCCNCCCN)(O)=O.O.O.O

InChI

1S/C5H15N2O3PS.3H2O/c6-2-1-3-7-4-5-12-11(8,9)10;;;/h7H,1-6H2,(H2,8,9,10);3*1H2

InChIKey

TXQPXJKRNHJWAX-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Amifostine may provide renal protection during PRRT using somatostatin analogs by mitigating radiation damage and reducing the absorbed kidney radiation dose. Amifostine remediates the degenerative effects of radiation on the mineralization capacity of the murine mandible.

Biochem./physiol. Wirkung

Radioprotective agent. Selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy. Selectivity is due to preferential uptake by normal tissues and subsequent metabolic activation to 2-(3-aminopropyl)aminoethanethiol.

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

H-Sätze

H302

Gefahreneinstufungen

Acute Tox. 4 Oral

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Gloves

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Ourania Nicolatou-Galitis et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 21(1), 357-364 (2012-10-12)
The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. A systematic
Melanie Duval et al.
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 41(5), 309-315 (2012-10-25)
The effectiveness of amifostine in the prevention of cisplatin ototoxicity remains controversial. The objective of this meta-analysis was to determine whether amifostine is successful in preventing ototoxicity secondary to cisplatin chemotherapy. Meta-analysis. We conducted a systematic review of all randomized
Henry L Gómez et al.
Hematology/oncology and stem cell therapy, 5(3), 152-157 (2012-10-26)
We report the 8-year follow-up of 34 patients aged ≥69 years old with NHL included in a phase IIb open-label randomized parallel groups study to evaluate the effectiveness of amifostine in preventing the toxicity of cyclophosphamide, doxorubicin, vincristine and prednisone
Murat Caloglu et al.
Journal of cancer research and therapeutics, 8(2), 260-265 (2012-07-31)
The aim of the study was to compare the protective efficacy of l-carnitine (LC) to amifostine on radiation-induced acute small intestine damage. Thirty, 4-week-old Wistar albino rats were randomly assigned to four groups - Group 1: control (CONT, n =
Michael I Koukourakis et al.
International journal of radiation oncology, biology, physics, 85(1), e7-13 (2012-10-09)
Postmastectomy radiation therapy (PMRT) provides major local control and survival benefits. More aggressive radiation therapy schemes may, however, be necessary in specific subgroups, provided they are safely administered. We report the tolerance and efficacy of a highly accelerated and hypofractionated
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.